-
UK team develops novel skin patch for diabetes
biospectrumasia
April 16, 2018
The patch does not pierce the skin, instead it draws glucose out from fluid between cells across hair follicles.
-
UK team develops novel skin patch for diabetes
biospectrumasia
April 16, 2018
The patch does not pierce the skin, instead it draws glucose out from fluid between cells across hair follicles.
-
Adhesive patch offers bloodless diabetes monitoring
europeanpharmaceuticalreview
April 13, 2018
Scientists have created a non-invasive, adhesive patch, which promises the measurement of glucose levels through the skin without a finger-prick blood test…
-
ARKAY Therapeutics Submits Investigational New Drug (IND) Application for RK-01, a First-in Class ‘Beta-cell-centric’ Drug Combination Product for Type 2 Diabetes
biospace
April 12, 2018
First Human Proof-of-Concept (PoC) Trial to Test the Superiority of RK-01 over Metformin in Type 2 Diabetes Patients with Inadequate Glycemic Control.
-
ReShape Lifesciences Pioneers New Bio-electronic Technology for Treatment of Type 2 Diabetes
biospace
April 11, 2018
?ReShape Lifesciences?Inc. announced today that the Company will be presenting early results of a new, novel use of the ReShape Lifesciences? neuro-blocking technology in combination with separate-site vagus nerve stimulation for the treatment of type 2
-
Lilly and Sigilon to collaborate on cell encapsulation for diabetes
pharmaceutical-technolog
April 09, 2018
Eli Lilly and Sigilon Therapeutics have announced a strategic collaboration to develop encapsulated cell therapies for type 1 diabetes.
-
Eating Pecans May Cut Risk of Cardiovascular Disease, Diabetes
drugs
April 09, 2018
Eating pecans every day for four weeks improves certain markers of cardiometabolic disease risk, according to a study published online March 11 in?Nutrients.
-
EMA to review Sanofi’s type I diabetes therapy
pharmatimes
March 30, 2018
The European Medicines Agency has accepted for review Sanofi's experimental type I diabetes therapy sotagliflozi.
-
Real world data back Sanofi’s Toujeo for type I diabetes
pharmatimes
March 21, 2018
Sanofi has unveiled real-world data from the UK showing the efficacy of its long-acting basal insulin analogue Toujeo in treating patients with type I diabetes.
-
AstraZeneca Presents New Data Evaluating Safety and Efficacy of FARXIGA in Patients with Type 2 Diab
biospace AstraZeneca today announced the results o
March 20, 2018
?AstraZeneca?today announced the results of DERIVE, a Phase 3 study that evaluated the efficacy and safety of FARXIGA?(dapagliflozin 10 mg), in patients with type 2 diabetes (T2D) with moderate renal impairment
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
